Risk factors

Mereo BioPharma Group (MREO) risk factors

Item 1A of every Mereo BioPharma Group plc 10-K on file, and what changed from one year to the next.

Open MREO in Gloomberb →
  • FY2025 10-K risk factors

    80 risks, 6 new, 3 dropped, 20 reworded since the prior year. Drug-pricing pressure is newly tied to the May 2025 U.S. most-favored-nation executive order and potential international measures.

    Filed Mar 19, 2026
  • FY2024 10-K risk factors

    77 risks. Clinical-stage biopharmaceutical company with cumulative losses and no product revenue, developing setrusumab, alvelestat, etigilimab, acumapimod, and leflutrozole.

    Filed Mar 26, 2025